| 前收盘价格 | 2.81 |
| 收盘价格 | 2.79 |
| 成交量 | 151,748 |
| 平均成交量 (3个月) | 1,949,388 |
| 市值 | 101,153,200 |
| 预期市盈率 (P/E Forward) | 3.72 |
| 价格/销量 (P/S) | 2.19 |
| 股市价格/股市净资产 (P/B) | 0.810 |
| 52周波幅 | |
| 利润日期 | 14 Aug 2023 - 18 Aug 2023 |
| 营业利益率 (TTM) | -3,350.19% |
| 稀释每股收益 (EPS TTM) | -0.560 |
| 季度收入增长率 (YOY) | -81.30% |
| 总债务/股东权益 (D/E MRQ) | 4.92% |
| 流动比率 (MRQ) | 5.83 |
| 营业现金流 (OCF TTM) | -27.47 M |
| 杠杆自由现金流 (LFCF TTM) | -15.32 M |
| 资产报酬率 (ROA TTM) | -24.32% |
| 股东权益报酬率 (ROE TTM) | -43.47% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 看涨 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 看涨 | |
| 股票 | SCYNEXIS, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 3.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.67 |
|
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Value |
| 内部持股比例 | 1.89% |
| 机构持股比例 | 29.83% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合